Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 17, 2026

Back to today

Semtech Analyst Day Review

Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper interconnect businesses.

SMTC $16B
CV's Substack 12 clicks

From X

@convequity 13 clicks

Convequity on X

We think the gross margin gap between Cerebras ($CBRS) and NVIDIA ($NVDA) says little about which company delivers compute more cheaply. Cerebras reported a 14% gross margin in Q2 2026, against roughly 75% for NVIDIA. That is not a clean comparison, because Cerebras's commercial agreements include customer warrants. A customer warrant gives a buyer of Cerebras compute the right to buy Cerebras shares at an agreed price, adding potential equity upside to the compute it purchases. Cerebras records the value of these incentives over time as a reduction in revenue. Its cost of delivering the compute stays the same, so the full amount comes out of gross profit and its reported gross margin falls too. Add the warrants and a few other items back and Cerebras's Q2 margin was 41%, so the reported gap tells us little about what each company spends to deliver equivalent compute. Cerebras could challenge NVIDIA with attractive economics on selected workloads without matching every capability of NVIDIA's platform. In our view NVIDIA's stronger answer is Feynman reaching customers on schedule with the 3D-stacked SRAM we expect. Stacking more fast memory close to the compute would reduce the need to fetch data from slower external memory, helping NVIDIA narrow the architectural advantage behind Cerebras's fast inference. NVIDIA's adoption of Groq technology could ease some of this pressure, but we believe Groq's current architecture remains weaker than Cerebras's for low-latency inference. The longer Feynman takes to arrive at scale, the more time Cerebras has to win customers.

Investor Letters

All letters

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

CRWV $34B
WHAT ARE WE DOING? “Contrarians At The Gate” 52 clicks

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

APP $88B
Speedwell Research 27 clicks

Constellation: Stars Aligning?

Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…

STZ $22B
TSOH Investment Research 27 clicks

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI…

CMG $39B
Yet Another Value Podcast 87 clicks
ZTS · long

Zoetis INC

Zoetis, the animal prescription-medicines company, is presented as a long investment despite concerns around its 2026 and 2027 outlook.

ZTS $31B
Value Investors Club 3 clicks

[VRSK] Verisk has standards

Verisk’s exit from healthcare, financial-services and energy data restored a pure-play insurance analytics model, but D.E.

VRSK $25B
scuttleblurb 1 click

Brown & Brown

Brown & Brown compounded revenue 14.4% annually since 1998 through more than 650 acquisitions, capped by its nearly $10 billion Accession…

BRO $23B
Eagle Point Capital

When the Ducks are Quacking

Ford’s 1956 IPO sold 10.2 million shares at $63 each after Goldman Sachs helped resolve the Ford Foundation’s voting-rights problem.

F $49B
Net Interest

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 108

YouTube 4

Blogs 17

Seeking Alpha 52 of 240

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

89 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.